Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642603 · ClinicalTrials.gov registry record · Phase 2
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00642603 is a Phase 2 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 41 participants.
The verdict
NCT00642603, a Phase 2 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of Xeloda and Avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with metastatic colorectal cancer. Patients were randomized to receive 2-weekly cycles of treatment with either: 1) Xeloda, Avastin and oxaliplatin; or 2) Xeloda, Avastin and irinotecan. After 9 cycles, patients continued to receive maintenance treatment with Xeloda + Avastin. The anticipated time on study treatment was until disease progression, and the target sample size was 100-500 individuals.
Interventions
- DRUG oxaliplatin
- DRUG irinotecan
- DRUG capecitabine [Xeloda]
- DRUG bevacizumab [Avastin]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642603
The ClinicalTrials.gov registry entry for NCT00642603 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which oxaliplatin is the first listed.
NCT00642603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642603 about?
NCT00642603 is a clinical study titled "A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer". This 2-arm study was designed to evaluate the efficacy and safety of 2 treatment regimens of Xeloda and Avastin, with either irinotecan or oxaliplatin administered for the first 12 cycles, as first line treatment in patients with metastatic colorectal cancer. Patients were randomized to receive 2-we...
What is the current status of trial NCT00642603?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2008-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00642603?
The interventions under investigation include: oxaliplatin (DRUG), irinotecan (DRUG), capecitabine [Xeloda] (DRUG), bevacizumab [Avastin] (DRUG).
Who is sponsoring clinical trial NCT00642603?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.